{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"CytoMed Therapeutics Limited"},"Symbol":{"label":"Symbol","value":"GDTC"},"Address":{"label":"Address","value":"Singapore"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Asia"},"CompanyDescription":{"label":"Company Description","value":"CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors."},"CompanyUrl":{"label":"Company Url","value":"https://w2.cytomed.sg"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jieming Zeng","title":"Director, Chief Scientific & Medical Officer"},{"name":"Tien Wee Luk","title":"Director & Chief Clinical Officer"},{"name":"Wee Kiat Tan","title":"Chief Executive Officer, COO & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}